Rucaparib trade name and drug registration information

Rucaparib's English nameRucaparib and its international trade name are Rubraca. In many regions around the world, Rubraca has been approved for indications in ovarian cancer, fallopian tube cancer, primary peritoneal cancer and prostate cancer with BRCA gene abnormalities. This drug is an oral PARP inhibitor that achieves anti-tumor effects by targeting the DNA repair mechanism of BRCA gene-deficient cancer cells. It is an important representative of precision targeted therapy.

In terms of registration information,Rubraca has been approved by the FDA in the United States and has obtained marketing authorization in many countries such as the European Union and Japan. In clinical registration trials, the drug showed significant efficacy in patients with BRCA mutations, including extended progression-free survival and improved quality of life. Drug registration is usually accompanied by rigorous clinical data support, including drug safety, efficacy and tolerability assessment, which provides patients with a reliable basis for clinical use.

Domestically,Rubraca has not yet completed marketing registration, so patients in China cannot obtain the drug through local channels. In the future, with the advancement of drug registration applications and submission of clinical data, Rubraca is expected to enter the domestic market and provide precise treatment options for tumor patients with specific genetic backgrounds. Before use, doctors usually recommend genetic testing to determine whether the patient is suitable for rucapani treatment, so as to achieve an individualized and precise treatment plan.

Generally speaking, Rucapanib's trade nameRubraca is an innovative PARP inhibitor for patients with BRCA gene mutations. It is mainly used for patients with ovarian cancer, fallopian tube cancer, primary peritoneal cancer and prostate cancer with BRCA gene abnormalities. It is a precise targeted therapy drug for specific genetic backgrounds. It has been launched in many regions around the world, but is still waiting for registration approval in China. Through precise targeting mechanisms, Rubraca provides an important option in the treatment of advanced or refractory tumors and brings new treatment hope to patients.

Reference materials:https://www.drugs.com/mtm/rucaparib.html